Evidence map›Paper›PMID 29052104›Full record

ArticleJournal of thrombosis and thrombolysis2018

Anticoagulation prescribing patterns in patients with cancer.

Elaine Xiang, Tania Ahuja, Veronica Raco, Frank Cirrone, David Green, John Papadopoulos

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 4 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Observational
  13. Review
  14. Observational
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Elaine XiangDepartment of Pharmacy, PGY-1 Pharmacy Resident, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA.ORCID http://orcid.org/0000-0001-8088-5010
Tania AhujaDepartment of Pharmacy, Clinical Pharmacotherapy Manager: Internal Medicine & Anticoagulation, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA. Tania.Ahuja@nyumc.org.ORCID http://orcid.org/0000-0003-1833-4124
Veronica RacoDepartment of Pharmacy, Clinical Pharmacotherapy Specialist: Internal Medicine, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA.ORCID http://orcid.org/0000-0003-0350-2316
Frank CirroneDepartment of Pharmacy, Clinical Pharmacotherapy Manager: Heamtology/Oncology, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA.
David GreenDepartment of Medicine, Antithrombotic Therapy Team, Medical Director, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA.
John PapadopoulosDepartment of Pharmacy, Director of Clinical Pharmacy Services, NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA.
NYU Langone Health · USRusk Rehabilitation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a known hypercoagulable state that leads to an increased risk of venous thromboembolism (VTE). Low molecular weight heparin remains the preferred anticoagulant for VTE in patients with cancer over vitamin K antagonist. However, the preferred anticoagulant in prevention of stroke and systemic embolism in atrial fibrillation (AF) in patients with cancer has yet to be determined. The direct oral anticoagulants (DOACs) are increasingly being utilized; however their role in cancer has only recently been investigated. The objective of this retrospective cohort was to describe real-world anticoagulation prescribing patterns in cancer patients at a large academic medical center between January 1, 2013 and October 31, 2016. We sought to assess the safety, tolerability, and efficacy of DOACs in patients with cancer for either VTE and/or AF. Patient demographic, clinical characteristics, as well as bleeding and thrombotic events were collected. There were 214 patients in our analysis, of which 71 patients (33%) received a DOAC [apixaban (n = 22), dabigatran (n = 17), and rivaroxaban (n = 32)]. There were fewer bleeding events and/or discontinuations in the DOAC group compared to enoxaparin (13 vs. 27, p = 0.022). There was no difference in major or minor bleeds or thromboembolic events in comparing DOAC to enoxaparin or DOAC to warfarin. This was a retrospective, single-institution study assessing the safety and efficacy of DOACs compared to warfarin or enoxaparin in patients with cancer. DOACs may represent an alternative to warfarin or enoxaparin in patients with cancer for VTE and/or stroke reduction in AF.

Indexed as

AdultAgedAnticoagulantsAtrial FibrillationDabigatranEnoxaparinHemorrhageHumansMiddle AgedNeoplasmsPractice Patterns, Physicians'PyrazolesPyridonesRetrospective StudiesRivaroxabanThrombosisAnticoagulantsapixabanDabigatranEnoxaparinPyrazolesPyridonesRivaroxabanWarfarinAnticoagulationAtrial fibrillationCancerDirect oral anticoagulantsLow molecular weight heparinVenous thromboembolism

Identifiers

PMID29052104
OpenAlexW2766141481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.